North America Urinalysis Market Dynamics and Trends by 2028

The urinalysis market in North America is expected to grow from US$ 1,432.01 million in 2021 to US$ 2,129.13 million by 2028; it is estimated to grow at a CAGR of 5.8% from 2021 to 2028.

The US, Canada, and Mexico are major economies in North America. As per the study reported by a group of researchers at the American College of Physicians and Infectious Diseases Society of America in 2020, ~6 million people in the US visit physicians for the treatment of urinary tract infection (UTIs) every year. Women are at a higher risk of developing UTIs than men. According to a study published in the International Journal of Environmental Research and Public Health in 2019, patients with existing chronic conditions, such as diabetes mellitus (DM), are at a greater risk of acquiring UTIs. The demand for components required for urinalysis is rising due to the common occurrence of diabetes across the region, as the primary screening for diabetes involves urinalysis. Moreover, according to a study published by the National Kidney Foundation in 2020, ~35.0% of the diabetic population above age 20 would develop chronic kidney diseases over the period. An ongoing surge in the prevalence of prostate and bladder cancer raises a strong therapeutic imperative for the implementation of highly effective diagnostics. Thus, the escalating prevalence of UTIs, diabetes, and kidney diseases boosts urinalysis market growth.

Lockdowns enacted by various North American countries to control the spread of COVID-19 caused people to delay undergoing health checkups, thus affecting the number of tests performed and sales of instruments, consumables, and reagents. However, a resurgence in testing numbers is seen as countries gradually ease the restrictions imposed on movement. According to National Kidney Foundation, people hospitalized with COVID-19 are at a significant risk of acute kidney injury (AKI), leading to serious illness, dialysis, and death. For the recovered COVID-19 patients who had an AKI or acute renal failure, urinalysis diagnosis is recommended since the risk of developing chronic kidney disease is higher in them than others. COVID-19 patients who did not develop an AKI, but had blood and/or protein in their urine, need to be monitored as they are at a greater risk of developing chronic- and end-stage kidney disease. COVID-19 has also impacted the regulatory environment and practices, as governments and healthcare providers are facing unprecedented challenges. Regulatory authorities utilized methods to speed approval of diagnostic products. Companies have taken strategic developments to introduce COVID-19 rapid tests, sustain their revenues, and nullify the impact of COVID-19 on their operational capabilities. For instance, in August 2020, Sysmex America, Inc., a leading diagnostic solutions company, entered into a distribution agreement with Siemens Healthineers to increase the distribution of the CLINITEK Novus automated urine chemistry analyzer platform.Therefore, in the long run, upon the streamlining of the COVID-19 vaccination programs and the decrease in transmission rates, healthcare systems will return to normal and generate significant demand urinalysis products and services

.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America urinalysis market. The North America urinalysis market is expected to grow at a good CAGR during the forecast period.

North America UrinalysisMarket Revenue and Forecast to 2028 (US$ Million)

North America Urinalysis Market Segmentation  

North America Urinalysis Market – By Product

• Consumables
• Instruments

North America Urinalysis Market – By Test Type

• Pregnancy and Fertility Tests
• Biochemical Urinalysis
• Sediment Urinalysis

North America Urinalysis Market – By Application

• Disease Screening
• Pregnancy and Fertility

North America Urinalysis Market – By End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Home Care Settings
• Research Laboratories and Institutes

North America Urinalysis Market, by Country

• US
• Canada
• Mexico

North America Urinalysis Market - Companies Mentioned

• Abbott    
• ACON Laboratories, Inc.             
• ARKRAY, Inc.     
• Beckman Coulter, Inc.     
• Bio-Rad Laboratories Inc.            
• Cardinal Health Inc         
• F. Hoffmann-La Roche Ltd.          
• Quidel Corporation          
• Siemens Healthineers AG           
• Sysmex Corporation

North America Urinalysis Report Scope